Prescient Therapeutics Limited

Operating from Melbourne, Australia, Prescient Therapeutics Limited is a clinical-stage oncology company dedicated to pioneering novel pharmaceutical treatments for a variety of cancers. The company's primary investigational therapy, PTX-200, is currently undergoing several advanced clinical trials: a Phase 2a study for HER2-negative breast cancer, a Phase 1B/2 trial addressing relapsed and refractory acute myeloid leukemia (AML), and a Phase 1b trial for platinum-resistant ovarian cancer that has recurred or persisted. Another key pipeline asset is PTX-100, a RhoA inhibitor, engineered to combat both blood and solid tumors, particularly those characterized by specific Ras and RhoA genetic mutations. Furthermore, Prescient maintains a strategic partnership with The University of Texas MD Anderson Cancer Center, focused on the development of a novel blood cancer binder for their OmniCAR platform. Established in 1986, the company adopted its current name, Prescient Therapeutics Limited, in December 2014, having previously operated as Virax Holdings Limited.